Tegoprazan

替戈拉生

Report date: 2024/12/03 17:16:26
NME

Base Information

Drug NameTegoprazan
Drug Alias Name特戈拉赞tegoprazanumK-Cab Tab泰欣赞CJ-12420 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium-transporting ATPase inhibitors
TargetsPotassium-transporting ATPase
Therapy Area/IndicationsHelicobacter pylori infectionHepatic InsufficiencyStomach Ulcer +[6] 
Global Approved IndicationsGastroesophageal Reflux
Approved Indications in ChinaGastroesophageal Reflux
Original Approved Country/TerritorySouth Korea
Original Approved Date2018/07/05
Country/TerritoryUnited StatesSouth KoreaIndia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSouthern XPHK Inno N CorpSebela Pharmaceuticals Inc +[7] 
Inactive CompaniesN/A
Active IndicationsHelicobacter pylori infectionDuodenal UlcerEsophagitis +[4] 
Inactive IndicationsHepatic InsufficiencyStomach Ulcer

Other Information

ATC CodeA02BC09
Related LinksDrugBankKEGG